Belite Bio to present Phase 3 DRAGON topline results for tinlarebant in adolescent Stargardt disease at Euretina
BLTE•Belite Bio scheduled oral presentations at Euretina meetings in Vienna, including Phase 3 DRAGON topline results for tinlarebant in adolescent Stargardt disease on Oct. 4, 2026. The results have not yet been presented.
1. Euretina presentations
Belite Bio scheduled oral presentations at Euretina meetings in Vienna, including the Phase 3 DRAGON topline results for tinlarebant in adolescent Stargardt disease. The readout is set for Oct. 4, 2026, and the results have not yet been presented.
